Nektar's Revenue Halves Amid Product Sales Halt, Net Loss Widens

TL;DR

**Nektar's cash burn and lack of product sales make it a risky bet; avoid until rezpegaldesleukin shows clear clinical wins.**

AI Summary

NEKTAR THERAPEUTICS reported a significant decline in total revenue for the nine months ended September 30, 2025, dropping to $33.425 million from $69.252 million in the prior year, a decrease of 51.7%. This was primarily driven by the cessation of product sales, which were $0 in 2025 compared to $20.689 million in 2024. The company's net loss for the nine months ended September 30, 2025, increased slightly to $127.997 million from $126.222 million in the same period last year. Research and development expenses decreased by 4.9% to $87.618 million from $92.163 million, while general and administrative expenses also saw a modest reduction of 3.7% to $57.488 million. Cash and cash equivalents decreased to $41.032 million as of September 30, 2025, from $44.252 million at December 31, 2024. The company's strategic outlook is heavily dependent on the success of rezpegaldesleukin and its ability to secure future collaboration agreements, as indicated by the substantial future capital requirements and reliance on collaboration revenue. The company also completed a secondary offering and an at-the-market offering, raising capital and increasing common stock outstanding to 19,652,513 shares.

Why It Matters

Nektar's substantial revenue decline, primarily due to the absence of product sales, signals a critical juncture for investors. The company's future hinges on the clinical success of rezpegaldesleukin and its ability to forge new, lucrative collaboration partnerships in a highly competitive biopharmaceutical landscape. This financial performance could impact employee morale and job security, as further cost-saving measures may be necessary. For customers, delays in drug development or commercialization could mean fewer treatment options. The broader market will watch to see if Nektar can pivot effectively, as its struggles highlight the inherent risks in drug development and the importance of a diversified pipeline.

Risk Assessment

Risk Level: high — The company explicitly states, 'we expect to continue to incur substantial net losses from operations and may not achieve or sustain profitability in the future.' Furthermore, total revenue for the nine months ended September 30, 2025, plummeted by 51.7% to $33.425 million, largely due to $0 in product sales compared to $20.689 million in the prior year, indicating a significant loss of a revenue stream. The company also highlights 'substantial future capital requirements' and dependence on collaboration agreements, which are uncertain.

Analyst Insight

Investors should exercise extreme caution and consider divesting or avoiding NKTR shares given the significant revenue decline and ongoing net losses. Monitor closely for concrete positive clinical trial data for rezpegaldesleukin and the announcement of new, substantial collaboration agreements, as these are critical for future viability.

Financial Highlights

debt To Equity

2.54

revenue

$33.425M

operating Margin

N/A

total Assets

$301.347M

total Debt

$216.261M

net Income

-$127.997M

eps

-$8.14

gross Margin

N/A

cash Position

$41.032M

revenue Growth

-51.7%

Revenue Breakdown

Key Numbers

• $33.425M — Total Revenue (Down 51.7% for the nine months ended September 30, 2025, from $69.252M in 2024.)
• $0 — Product Sales (For the nine months ended September 30, 2025, down from $20.689M in 2024, indicating a complete cessation.)
• $127.997M — Net Loss (Increased from $126.222M for the nine months ended September 30, 2024.)
• $87.618M — Research and Development Expenses (Decreased by 4.9% from $92.163M for the nine months ended September 30, 2024.)
• $41.032M — Cash and Cash Equivalents (As of September 30, 2025, down from $44.252M at December 31, 2024.)
• 19,652,513 — Common Stock Shares Outstanding (As of September 30, 2025, significantly increased from 12,385,001 at December 31, 2024, due to offerings.)
• $1.87 — Basic and Diluted Net Loss Per Share (Q3 2025) (Improved from $(2.66) in Q3 2024, despite higher net loss, due to increased share count.)
• $8.14 — Basic and Diluted Net Loss Per Share (YTD 2025) (Improved from $(9.27) in YTD 2024, despite higher net loss, due to increased share count.)

Key Players & Entities

• NEKTAR THERAPEUTICS (company) — registrant
• Eli Lilly and Company (company) — collaboration partner
• NASDAQ Capital Market (regulator) — exchange where common stock is registered
• rezpegaldesleukin (drug) — key drug candidate
• $33.425 million (dollar_amount) — total revenue for nine months ended September 30, 2025
• $69.252 million (dollar_amount) — total revenue for nine months ended September 30, 2024
• $127.997 million (dollar_amount) — net loss for nine months ended September 30, 2025
• $126.222 million (dollar_amount) — net loss for nine months ended September 30, 2024
• $41.032 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• 19,652,513 (dollar_amount) — shares outstanding as of September 30, 2025

FAQ

Risk Factors

• Substantial Future Capital Requirements [high — financial]: The company has significant future capital requirements and relies on collaboration revenue and potential future financing. As of September 30, 2025, cash and cash equivalents were $41.032 million, a decrease from $44.252 million at December 31, 2024. The company's ability to continue as a going concern is dependent on its ability to secure future funding and generate revenue.
• Dependence on Key Drug Development [high — operational]: The company's strategic outlook is heavily dependent on the success of rezpegaldesleukin. Clinical trial outcomes and regulatory approvals for this drug are critical for future revenue generation. Any setbacks in development or approval processes pose a significant risk.
• Increased Net Loss and Decreased Revenue [high — financial]: For the nine months ended September 30, 2025, total revenue declined 51.7% to $33.425 million from $69.252 million in the prior year. The net loss increased slightly to $127.997 million from $126.222 million, indicating ongoing operational challenges.
• Dilution from Equity Offerings [medium — financial]: The company completed a secondary offering and an at-the-market offering, significantly increasing common stock outstanding to 19,652,513 shares as of September 30, 2025, from 12,385,001 shares outstanding at December 31, 2024. This dilutes existing shareholders' ownership.
• Reliance on Collaboration Agreements [high — operational]: The company's ability to fund its operations and development activities is substantially dependent on securing future collaboration agreements. A failure to secure or maintain these partnerships could severely impact its financial stability.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Nektar Therapeutics rely heavily on successful drug development and strategic partnerships to generate revenue and fund operations. The competitive landscape is intense, with many companies vying for market share in therapeutic areas.

Regulatory Implications

Nektar Therapeutics operates within a highly regulated industry. The success of its drug candidates, such as rezpegaldesleukin, is contingent upon obtaining approvals from regulatory bodies like the FDA. Any delays or rejections in the approval process represent a significant risk to the company's financial health and future prospects.

What Investors Should Do

1. Monitor progress of rezpegaldesleukin development and regulatory filings.
2. Assess the company's ability to secure future collaboration agreements and funding.
3. Evaluate the impact of increased share count on future earnings per share.

Key Dates

• 2025-09-30: Nine Months Ended — Reported total revenue of $33.425 million, a 51.7% decrease year-over-year, and a net loss of $127.997 million.
• 2025-09-30: Balance Sheet Date — Cash and cash equivalents stood at $41.032 million, and total assets were $301.347 million.
• 2025-09-30: Common Stock Outstanding — 19,652,513 shares outstanding, reflecting increases from equity offerings.

Glossary

Rezpegaldesleukin

A specific drug candidate being developed by Nektar Therapeutics. (The success of this drug is critical to the company's future revenue and strategic outlook.)

Equity Method Investment

An accounting method where an investment in another company is recorded at cost and adjusted for the investor's share of the investee's net income or loss. (The company has an equity method investment in Gannet BioChem, which was $4.837 million as of September 30, 2025, down from $12.218 million at December 31, 2024.)

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income. (Nektar Therapeutics has a significant accumulated deficit of $(3,724,207,000) as of September 30, 2025, indicating a history of net losses.)

At-the-Market Offering (ATM)

A type of stock offering where a company sells shares of its stock on a public exchange at the prevailing market price. (Nektar Therapeutics utilized an ATM offering to raise capital, which increased its outstanding shares.)

Reverse Stock Split

A corporate action to reduce the number of outstanding shares of stock by consolidating them into fewer, proportionally more valuable shares. (The financial statements reflect a one-for-fifteen reverse stock split that occurred prior to the reporting period.)

Year-Over-Year Comparison

Total revenue for the nine months ended September 30, 2025, has fallen sharply by 51.7% to $33.425 million, primarily due to the complete cessation of product sales. While R&D and G&A expenses saw modest decreases, the net loss widened slightly to $127.997 million. Cash reserves have decreased, and the company has significantly increased its outstanding shares through equity offerings, indicating a challenging financial position compared to the prior year.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR NASDAQ Capital Marke

Filing Documents

• nktr-20250930.htm (10-Q) — 2764KB
• nktr-ex31_1.htm (EX-31.1) — 15KB
• nktr-ex31_2.htm (EX-31.2) — 15KB
• nktr-ex32_1.htm (EX-32.1) — 11KB
• 0001193125-25-270230.txt ( ) — 9766KB
• nktr-20250930.xsd (EX-101.SCH) — 1194KB
• nktr-20250930_htm.xml (XML) — 1755KB

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements — Unaudited: 6 Condensed Consolidated Balance Sheets — September 30, 2025 and December 31, 2024 6 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 8 Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2025 and 2024 9 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 11 Notes to Condensed Consolidated Financial Statements 12 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 40 Item 4.

Controls and Procedures

Controls and Procedures 40

: OTHER INFORMATION

PART II: OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 66 Item 3. Defaults Upon Senior Securities 66 Item 4. Mine Safety Disclosures 66 Item 5. Other Information 66 Item 6. Exhibits 67

Signatures

Signatures 69 2 Table of Contents

Forward-Looking Statements

Forward-Looking Statements This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are "forward-looking statements" for purposes of this Quarterly Report on Form 10-Q, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements related to our strategic reorganization and cost restructuring plans, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates and our future research and development plans, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of any collaboration arrangements, commercialization activities and product sales levels and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation (including the timing for court hearings and trials) and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as "believe," "may," "will," "expects," "plans," "anticipates," "estimates," "potential" or "continue," or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the

: FINANCI AL INFORMATION

PART I: FINANCI AL INFORMATION

Condensed Consolidated Financial Statements—Unaudited

Item 1. Condensed Consolidated Financial Statements—Unaudited: NEKTAR THERAPEUTICS CONDENSED CONSOLID ATED BALANCE SHEETS (In thousands, except share and per share data) (Unaudited) September 30, 2025 December 31, 2024 (1) ASSETS Current assets: Cash and cash equivalents $ 41,032 $ 44,252 Short-term investments 229,176 210,974 Other current assets (including $ 177 and $ 0 as of September 30, 2025 and December 31, 2024, respectively, from a related party) 11,149 6,066 Total current assets 281,357 261,292 Long-term investments — 13,869 Property and equipment, net 2,826 3,411 Operating lease right-of-use assets 7,171 8,413 Equity method investment in Gannet BioChem 4,837 12,218 Other assets 5,156 4,647 Total assets $ 301,347 $ 303,850 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 15,563 $ 11,560 Accrued expenses (including $ 316 and $ 3,403 as of September 30, 2025 and December 31, 2024, respectively, to a related party) 28,594 29,972 Operating lease liabilities, current portion 22,183 19,868 Total current liabilities 66,340 61,400 Operating lease liabilities, less current portion 69,732 82,696 Liabilities related to the sales of future royalties, net 75,164 91,776 Other long-term liabilities 5,025 7,241 Total liabilities 216,261 243,113 Commitments and contingencies Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at September 30, 2025 or December 31, 2024, respectively — — Common stock, $ 0.0001 par value; 390,000,000 shares and 300,000,000 shares authorized at September 30, 2025 and December 31, 2024; 19,652,513 shares and 12,937,308 shares issued at September 30, 2025 and December 31, 2024, respectively; 19,652,513 shares and 12,385,001 shares outstanding at September 30, 2025 and December 31, 2024, respectivel

View Full Filing

View this 10-Q filing on SEC EDGAR